HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome.

Abstract
Evidence has linked neutrophil elastase to acute respiratory distress syndrome (ARDS), suggesting that inhibiting the activity of this enzyme could prevent the development and progression of ARDS. However, few clinical trials have examined this notion. We therefore examined the effects of ONO-5046 (sivelestat, a specific inhibitor of neutrophil elastase; sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylaminobenzoyl]amino-acetate tetrahydrate]) in a randomized, double-blinded trial in patients with ARDS. We randomly assigned 24 patients with ARDS to groups that received conventional therapy without or with sivelestat (0.2 mg. kg(-1). h(-1)) for 14 days. The variables of interest associated with clinical outcome were the duration of mechanical ventilation; changes in oxygenation from baseline; changes in cytokine levels from baseline; number of patients alive at 30 days who did not need mechanical ventilation; and mortality rate. The length of intensive care unit stay, number of ventilation days, and mortality rates did not statistically differ between groups. ARDS was more persistent in the control than in the sivelestat group (control, 19.5 +/- 7.4 days; sivelestat, 13.5 +/- 5.9 days; P = 0.039). Neutrophil elastase activity significantly differed between groups at 72 h after treatment. Levels of interleukin-6 were lower in the sivelestat group than in the controls at 24, 48, and 72 h after treatment. ONO-5046 apparently did not affect survival or the duration of mechanical ventilation.
AuthorsYuji Kadoi, Hiroshi Hinohara, Fumio Kunimoto, Shigeru Saito, Fumio Goto, Takayuki Kosaka, Keisuke Ieta
JournalAnesthesia and analgesia (Anesth Analg) Vol. 99 Issue 3 Pg. 872-877 (Sep 2004) ISSN: 0003-2999 [Print] United States
PMID15333424 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cytokines
  • Serine Proteinase Inhibitors
  • Sulfonamides
  • sivelestat
  • Leukocyte Elastase
  • Glycine
Topics
  • Adult
  • Aged
  • Cytokines (blood)
  • Double-Blind Method
  • Female
  • Glycine (analogs & derivatives, pharmacology, therapeutic use)
  • Humans
  • Leukocyte Elastase (antagonists & inhibitors)
  • Male
  • Middle Aged
  • Pilot Projects
  • Respiratory Distress Syndrome (drug therapy)
  • Serine Proteinase Inhibitors (therapeutic use)
  • Sulfonamides (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: